Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma.

MLA

Homsi, Jade, et al. “Phase 2 Open-Label Study of Weekly Docosahexaenoic Acid-Paclitaxel in Patients with Metastatic Uveal Melanoma.” Melanoma Research, vol. 20, no. 6, Dec. 2010, pp. 507–10. EBSCOhost, https://doi.org/10.1097/CMR.0b013e3283403ce9.

APA

Homsi, J., Bedikian, A. Y., Papadopoulos, N. E., Kim, K. B., Hwu, W.-J., Mahoney, S. L., & Hwu, P. (2010). Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma. Melanoma Research, 20(6), 507–510. https://doi.org/10.1097/CMR.0b013e3283403ce9

Chicago

Homsi, Jade, Agop Y Bedikian, Nicholas E Papadopoulos, Kevin B Kim, Wen-Jen Hwu, Sandy L Mahoney, and Patrick Hwu. 2010. “Phase 2 Open-Label Study of Weekly Docosahexaenoic Acid-Paclitaxel in Patients with Metastatic Uveal Melanoma.” Melanoma Research 20 (6): 507–10. doi:10.1097/CMR.0b013e3283403ce9.